25.03.2019 Views

Medikal Teknik Mart 2019

Medikal Teknik Mart 2019

Medikal Teknik Mart 2019

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

March / <strong>Mart</strong> <strong>2019</strong> 62<br />

2030 yılında kanserin<br />

birinci ölüm nedeni<br />

olacağı ve kanser<br />

vakalarındaki artışın<br />

ise yüzde 50’yi bularak,<br />

her yıl 15 milyon kişinin<br />

kansere yakalanacağı<br />

öngörülmektedir “ dedi.<br />

today, but also for future generations as well. According to the<br />

World Cancer Report, it is predicted that the first death cause will<br />

be cancer in 2030 and the increase in cancer cases will reach to<br />

50% and 15 million people will catch cancer every year” she said.<br />

We have new drugs in our target<br />

Dr Hande Demirdere,<br />

Turkey General<br />

Manager of Pierre Fabre<br />

Pharmaceuticals who<br />

has expressed that as a<br />

pharmaceutical company<br />

that serves human<br />

health, their main tasks<br />

are to contribute to the<br />

relief and recovery of the<br />

challenging disease and<br />

treatment process by<br />

offering treatment options<br />

to the cancer patients,<br />

continued as follows. “We<br />

are aiming to add new<br />

medicines to treatment<br />

areas by strengthening<br />

with global agreements<br />

in order to better respond<br />

to the needs of patients in<br />

Turkey with our patientcentred<br />

approach and our<br />

experience over the years”<br />

she said.<br />

Hedefimizde yeni<br />

ilaçlar var<br />

İnsan sağlığına<br />

hizmet eden bir ilaç<br />

firması olarak başlıca<br />

görevlerinin, kanser<br />

hastalarına tedavi<br />

seçeneği sunarak, zorlu<br />

olan hastalık ve tedavi<br />

sürecini rahatlatmaya<br />

ve iyileşmelerine katkıda<br />

bulunmak olduğunu<br />

ifade eden Pierre Fabre<br />

İlaç Türkiye Genel<br />

Müdürü Dr. Hande<br />

Demirdere, “Hasta<br />

odaklı yaklaşımımızla<br />

yıllar içinde edindiğimiz<br />

tecrübemizi, Türkiye’deki hastaların ihtiyaçlarına daha<br />

iyi cevap verebilmek amacıyla global anlaşmalarla<br />

güçlendirerek tedavi alanlarına yeni ilaçlar eklemeyi<br />

hedeflemekteyiz.” dedi.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!